PDCD1 and neoplasm: At laboratory level, Lenvatinib plus PD-1 blockade therapy was found to enhance the potency of effector T cells adjoint with decrease of monocytes and tumor associated macrophages, thus reach a preponderant antitumor effectiveness [175–177].